RESEARCH TRIANGLE PARK – GlaxoSmithKline is acquiring oncology firm Tesaro in a deal worth $5.1 billion just hours after announcing the sale of its health drinks business in India to Unilever for some $3.7 billion.
“The proposed transaction significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology,” GSK said in a statement announcing the Tesaro deal early Monday.
It’s all cash with GSK paying $75 a share.
Zejula brought in $166 million in revenue in the first nine months of this year, with third-quarter sales growing more than 60 percent.
Glaxo expects the deal to close in the first quarter.
Shares of Waltham, Massachusetts-based Tesaro Inc. jumped nearly 59 percent to $73.60 in morning trading.
“The acquisition of TESARO will strengthen our pharmaceuticals business by accelerating the build of our oncology pipeline and commercial footprint, along with providing access to new scientific capabilities,” said GSK Chief Executive Officer Emma Walmsley in a statement.
“This combination will support our aim to deliver long-term sustainable growth and is consistent with our capital allocation priorities. We look forward to working with Tesaro’s talented team to bring valuable new medicines to patients.”
Teasro has one marketed product, Zejula, which is approved for use in fighting ovarian cancer.
Trials are underway toexpand the use of the company’s oral poly ADP ribose polymerase (PARP) inhibitor technology.
Over the weekend, Unilever said it was buying the health food and drinks business of GSK in India, Bangladesh and 20 other mostly Asian markets.
Unilever will pay €3.3 billion ($3.7 billion) in cash and shares for the portfolio, which includes the malted milk drinks Horlicks and Boost. Both brands are popular in India.
In a statement, Walmsley noted: “Horlicks has made a significant contribution to GSK and to the health of consumers across India for many decades and we believe Unilever is well placed to maximize its future potential. Proceeds from this transaction will be used to support the Group’s strategic priorities, including investing in our pharmaceutical business.”
GSK said it expects to net more than $2 billion in the deal.
Shares in Unilever (UL) gained around 0.5% after the announcement. GlaxoSmithKline (NYSE: GSK) was trading 1% higher.
GSK operates an R&D facility in RTP and a manufacturing plant in Zebulon.